Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CYTK)
NASDAQ:CYTK
CYTK Stock Chart & Stats
$64.60
-$0.99(-2.05%)
At close: 4:00 PM EST
$64.60
-$0.99(-2.05%)
Day’s Range― - ―
52-Week Range$29.31 - $70.98
Previous CloseN/A
Volume107.14K
Average Volume (3M)1.96M
Market Cap
$7.90B
Enterprise Value$6.83B
Total Cash (Recent Filing)$962.53M
Total Debt (Recent Filing)$1.20B
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Mar 04, 2026EPS Estimate
-1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.55
Shares Outstanding122,264,930
10 Day Avg. Volume1,896,500
30 Day Avg. Volume1,959,422
Financial Highlights & Ratios
PEG Ratio2.56
Price to Book (P/B)-38.91
Price to Sales (P/S)285.13
P/FCF Ratio-13.18
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue78.26
Enterprise Value/Gross Profit-61.37
Enterprise Value/Ebitda-10.56
Forecast
1Y Price Target
$89.79Price Target Upside38.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)-5.76
Revenue Forecast (FY)$136.38M
Bulls Say, Bears Say
Bulls Say
Clinical Differentiation And Patient ExperienceAficamten's ability to be titrated more rapidly and to require fewer echocardiograms should improve patient convenience and reduce treatment interruptions versus current options.
Commercial Launch And Market PotentialEstablished commercial and medical affairs teams together with planned launch metrics on prescriber uptake and prescription volumes support expectations of a strong rollout and potential capture of treatment‑naive patients.
Regulatory And LabelFDA approval of Myqorzo with a manageable REMS and a straightforward dosing table reduces monitoring complexity and supports easier prescribing compared with the incumbent.
Bears Say
Dependence On Trial Outcomes For ExpansionCommercial upside depends on successful results from the ACACIA trial to support label expansion, leaving valuation exposed if topline outcomes fall short.
Incumbent Advantage And Market Share RiskA substantial first‑mover advantage for the incumbent creates uncertainty over how much market share the new product can capture and how quickly the category will expand.
Payer Access And ReimbursementDelays in achieving payer access parity and potential pricing disadvantages versus lower‑cost therapies could constrain early revenue and slow uptake.
Cytokinetics News
CYTK FAQ
What was Cytokinetics’s price range in the past 12 months?
Cytokinetics lowest stock price was $29.31 and its highest was $70.98 in the past 12 months.
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is $7.90B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Mar 04, 2026 which is in 46 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Nov 05, 2025. The company reported -$2.55 earnings per share for the quarter, missing the consensus estimate of -$1.571 by -$0.979.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.55.
How many shares outstanding does Cytokinetics have?
Cytokinetics has 122,264,930 shares outstanding.
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$2.55 in its last earnings report, missing expectations of -$1.571. Following the earnings report the stock price went up 1.875%.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CYTK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytokinetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$89.79 (38.99% Upside)
$89.79 (38.99% Upside)
Blogger Sentiment
Bullish
CYTK Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $9.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 19.2%
Last 30 Days ▲ 19.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
0.03%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
CYTK Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress towards the approval and commercial readiness of aficamten, supported by strong clinical trial results and a solid financial position. However, increased net loss and pending regulatory approvals present challenges.View all CYTK earnings summariesCYTK Stock 12 Month Forecast
Average Price Target
$89.79
▲(38.99% Upside)
Technical Analysis
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Legend Biotech
―
Avidity Biosciences
―
Nuvalent
―
Ownership Overview
Currently, No data available
---